Insider Selling: Pulmonx Co. (NASDAQ:LUNG) Director Sells $15,188.78 in Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 2,326 shares of Pulmonx stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $6.53, for a total value of $15,188.78. Following the completion of the transaction, the director now owns 1,069,648 shares of the company’s stock, valued at approximately $6,984,801.44. The trade was a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Pulmonx Price Performance

Shares of LUNG opened at $6.10 on Friday. The firm has a market capitalization of $240.89 million, a price-to-earnings ratio of -4.15 and a beta of 0.66. The stock’s fifty day moving average is $6.42 and its 200-day moving average is $6.88. Pulmonx Co. has a one year low of $5.46 and a one year high of $14.84. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $20.39 million for the quarter, compared to the consensus estimate of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same period in the previous year, the firm earned ($0.39) EPS. Equities analysts anticipate that Pulmonx Co. will post -1.53 EPS for the current year.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors have recently added to or reduced their stakes in the company. 272 Capital LP bought a new stake in shares of Pulmonx in the 3rd quarter worth $25,000. nVerses Capital LLC acquired a new position in Pulmonx during the third quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Pulmonx in the second quarter worth about $37,000. R Squared Ltd bought a new stake in Pulmonx in the fourth quarter worth about $46,000. Finally, SG Americas Securities LLC acquired a new stake in Pulmonx in the 3rd quarter valued at about $102,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wells Fargo & Company reduced their price objective on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Stifel Nicolaus lowered their price target on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Finally, Citigroup reaffirmed a “neutral” rating and issued a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.75.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.